Unknown

Dataset Information

0

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.


ABSTRACT: The runt-related transcription factor 1, RUNX1, is crucial in the development of myeloid and lymphoid cell lineages and has been reported to be mutated in myeloid malignancies in approximately 30% of cases. In this study, the mutational status of RUNX1 was investigated in 128 acute lymphoblastic leukemia patients. We detected a mutation rate of 18.3% (13 of 71) in patients with T-cell acute lymphoblastic leukemia, 3.8% (2 of 52) in patients with B-cell acute lymphoblastic leukemia and no mutation (0 of 5) in patients with natural killer cell leukemia, respectively. In T-cell acute lymphoblastic leukemia patients, RUNX1 mutations were significantly associated with higher age (P=0.017) and lower white blood cell count (P=0.038). Moreover, an inferior outcome was observed in the subgroup of early T-cell acute lymphoblastic leukemia patients carrying RUNX1 mutations for overall survival (P=0.043). In conclusion, RUNX1 mutations are an important novel biomarker for a comprehensive characterization of T-cell acute lymphoblastic leukemia with poor prognostic impact and have implications for use also in monitoring disease.

SUBMITTER: Grossmann V 

PROVIDER: S-EPMC3232273 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.

Grossmann Vera V   Kern Wolfgang W   Harbich Stefan S   Alpermann Tamara T   Jeromin Sabine S   Schnittger Susanne S   Haferlach Claudia C   Haferlach Torsten T   Kohlmann Alexander A  

Haematologica 20110809 12


The runt-related transcription factor 1, RUNX1, is crucial in the development of myeloid and lymphoid cell lineages and has been reported to be mutated in myeloid malignancies in approximately 30% of cases. In this study, the mutational status of RUNX1 was investigated in 128 acute lymphoblastic leukemia patients. We detected a mutation rate of 18.3% (13 of 71) in patients with T-cell acute lymphoblastic leukemia, 3.8% (2 of 52) in patients with B-cell acute lymphoblastic leukemia and no mutatio  ...[more]

Similar Datasets

| S-EPMC8405188 | biostudies-literature
| S-EPMC3701905 | biostudies-literature
| S-EPMC10332349 | biostudies-literature
| S-EPMC2847364 | biostudies-literature
| S-EPMC2817026 | biostudies-literature
| S-EPMC8409579 | biostudies-literature
| S-EPMC8722219 | biostudies-literature
| S-EPMC9101393 | biostudies-literature
| S-EPMC3622520 | biostudies-literature
| S-EPMC5630418 | biostudies-literature